GSK buys US-based rare cancer treatment developer for up to £1bn 0 13.01.2025 14:27 Evening Standard The acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal cancers. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
